CHOLANGIOCARCINOMA

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancers that have worsened after initial treatment. About 168 participants will receive either the combination or pa…

This study is testing whether a drug called tucatinib can be safely combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) to treat HER2-positive cancers of the digestive system. About 40 adults with advanced stomach, bowel, or gallbladder cancer are …

This study tested the drug pembrolizumab in over 1,600 people with various advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink or control the tumors. The trial focused on identifying which patients were most likel…

This early-phase study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, bone cancer, or brain tumors) that have certain IDH gene mutations. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the…

This phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…

This study tests a new drug called CGT4859 in people with bile duct cancer (cholangiocarcinoma) or other advanced solid tumors that have specific genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About …

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This study aimed to see if a person's own immune cells, modified in a lab to target specific cancer gene mutations, could prevent gastrointestinal cancers from coming back after standard treatment. It was designed for people with certain gene changes and blood markers suggesting …

This study aimed to compare two different needles used during endoscopy to collect tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis of cancer or other conditions. The study was planned for ad…

This early-stage trial is testing how safe radiation therapy is for people with liver cancer who also have liver damage from cirrhosis, chemotherapy, or surgery. The goal is to find the best dose that can kill cancer cells without causing severe side effects. The study includes 3…

This early-phase study tests a new imaging agent called 68Ga-FAPI-46, which targets cells around tumors. About 26 adults with various cancers will receive the tracer and then have a PET/CT scan. The goal is to see where the tracer goes in the body and compare it to standard imagi…

This study collects blood, urine, stool, and tissue samples from 132 adults with liver cancer who have had or will have immunotherapy. The goal is to build a large collection of samples and health data to better understand how liver cancer develops and responds to treatment. Part…

This study is testing a new blood test to see if it can find signs of bile duct cancer (cholangiocarcinoma) coming back or getting worse after treatment. Researchers will take blood samples before and after surgery or therapy to look for specific markers. The goal is to improve h…

This study looks at whether an exercise program before surgery is practical and safe for people aged 65 and older with liver or bile duct cancer. About 25 participants will do supervised exercise sessions at home and report on their progress. The goal is to see if patients can st…